Evidence map›Paper›PMID 19462507›Full record

ReviewGastroenterology2009

Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era.

Geoffrey A Preidis, James Versalovic

Abstract readReview
In one paragraph

Review in Gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Microbial lysate upregulates host oxytocin.Brain, behavior, and immunity · 2017
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Geoffrey A PreidisInterdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA.
James Versalovic

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
Modulation of NF-kB Signaling by ImmunoprobioticsR01AT004326 · NCCIH · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2008 to 2011
$1.8M
Intestinal Lactobacillus and Mucosal ImmunomodulationR01DK065075 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2007 to 2010
$1.3M
The Human Microbiome in Pediatric Abdominal Pain and Intestinal InflammationUH2DK083990 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2009 to 2009
$755k
Probiotic Lactobacillus-Mediated Suppression of TNF in Pediatric Crohn's DiseaseR21AT003482 · NCCIH · BAYLOR COLLEGE OF MEDICINE · PI VERSALOVIC, JAMES · 2007 to 2008
$408k
Mechanisms of Immunomodulation by Probiotic L. reuteri in Acute GastroenteritisF30DK081269 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI PREIDIS, GEOFFREY A · 2009 to 2011
$105k
NCCIH NIH HHS R01 AT004326NCCIH NIH HHS R21 AT003482NIDDK NIH HHS F30 DK081269NIDDK NIH HHS P30 DK056338NIDDK NIH HHS P30 DK56338NIDDK NIH HHS R01 DK065075NIDDK NIH HHS UH2 DK083990
6 · The paper itself

Abstract

Studies of metagenomics and the human microbiome will tremendously expand our knowledge of the composition of microbial communities in the human body. As our understanding of microbial variation and corresponding genetic parameters is refined, this information can be applied to rational remodeling or "tailoring" of human-associated microbial communities and their associated functions. Physiologic features such as the development of innate and adaptive immunity, relative susceptibilities to infections, immune tolerance, bioavailability of nutrients, and intestinal barrier function may be modified by changing the composition and functions of the microbial communities. The specialty of gastroenterology will be affected profoundly by the ability to modify the gastrointestinal microbiota through the rational deployment of antibiotics, probiotics, and prebiotics. Antibiotics might be used to remove or suppress undesirable components of the human microbiome. Probiotics can introduce missing microbial components with known beneficial functions for the human host. Prebiotics can enhance the proliferation of beneficial microbes or probiotics, to maximize sustainable changes in the human microbiome. Combinations of these approaches might provide synergistic and effective therapies for specific disorders. The human microbiome could be manipulated by such "smart" strategies to prevent and treat acute gastroenteritis, antibiotic-associated diarrhea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and a variety of other disorders.

Indexed as

Anti-Bacterial AgentsGastrointestinal DiseasesGastrointestinal TractHumansMetagenomeProbioticsAnti-Bacterial Agents

Identifiers

PMID19462507
PMCPMC4108289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.